<\/p>\n
Shelby Knowles \/ Bloomberg \/ Getty Images<\/p>\n
Eli Lilly shares have added over a third of their value in 2025, thanks in part to strong sales of the company’s weight-loss drugs <\/p>\n
Eli Lilly said Monday it is reducing the price of its Zepbound weight-loss drug on its platform LillyDirect.<\/p>\n<\/li>\n
The move comes about a month after the company announced a deal with the Trump administration to lower weight-loss drug costs.<\/p>\n<\/li>\n<\/ul>\n
Eli Lilly (LLY) said Monday that it’s lowering the price of its popular weight-loss drug Zepbound, about a month after striking a deal with the Trump administration to lower drug costs.<\/p>\n
The company said the price for a once-a-month single vial purchased through its LillyDirect digital health care platform will go down $50 for the 2.5-, 7.5-, 10-, 12.5-, and 15-milligram doses, and $100 for the 5-milligram dose. The prices range from $299 for the lowest dose to $449 for the highest.<\/p>\n
Lilly\u2019s decision to lower Zepbound pricing comes amid growing political pressure on the company to make its weight-loss drugs more affordable.<\/p>\n
The move follows a White House meeting in November, where the president and Lilly CEO David Ricks announced plans to make the company’s weight-loss drugs more affordable and accessible.<\/p>\n
As part of that deal, Lilly will make Zepbound and obesity pill Orforglipron available for no more than $50 a month<\/a> for Medicare recipients starting next April, pending Food and Drug Administration<\/a> approval.<\/p>\n In addition, the company agreed that for new medicines, it would take \u201ca more balanced pricing approach across developed nations.\u201d\u00a0 The Trump administration agreed to give Lilly three years of relief from tariffs, and it will not be subject to future pricing mandates.<\/p>\n Shares of Eli Lilly slid about 2% amid broader market losses Monday<\/a>, after hitting an all-time high last week. They’ve added over a third of their value in 2025.<\/p>\n